Responses
Regular and young investigator award abstracts
Clinical trials in progress
360 A phase 1 study of an Off-the-Shelf, multi-neoantigen vector (ADXS-503) alone and in combination with pembrolizumab in subjects with metastatic non-small cell lung cancer (NSCLC)
Compose a Response to This Article
Other responses
No responses have been published for this article.
